Build vs buy AI medical coding: a decision guide
For most organizations, buying or partnering is the faster, lower-risk path to AI medical coding — building in-house requires a sizable AI team, continuous model maintenance, and audit-ready governance. Building can make sense when data sovereignty or deep custom fit are overriding requirements, but you should model the full three-year total cost of ownership, not just year one. A hybrid third way — a bought system that's built on your data, transparent, and governed by your team — captures much of build's fit and control without its cost.
The real trade-off
The build-vs-buy decision isn't really “custom vs generic.” It's a trade between control and fit on one side and cost, time, and maintenance burden on the other.
| Build in-house | Buy / partner | |
|---|---|---|
| Upside | Full control, deep fit, data sovereignty | Speed, lower up-front cost, vendor keeps it current |
| Downside | Cost, time, talent, ongoing maintenance | Less control; risk of a generic fit or model lock-in |
| Best when | Fit / sovereignty are non-negotiable and you have the team | You need results soon and want to prove the use case first |
The cost of building (the part that's easy to underestimate)
In healthcare, data sensitivity (HIPAA, data sovereignty) pulls some teams toward building. But the economics are steep. Industry estimates put a minimal in-house AI team at roughly $420,000–$590,000 per year in salaries alone, and a more complete team well over $750,000 — before benefits, tooling, and ramp-up. And salaries are just the start:
- Maintenance never ends. AI behavior can drift even when the code doesn't, so you need continuous monitoring, evaluation, regression tests, and rollback plans.
- Audit-readiness is a standing cost. Codes and payer rules change; keeping a home-grown system compliant and defensible is ongoing work.
- Breakeven is far out. Analyses commonly model a multi-year payback — on the order of ~33 months — so the decision should be made on three-year TCO, not the first year.
The cost of buying (what to watch for)
Buying trades that burden for two risks worth screening: a generic fit that isn't adapted to your documentation and payers, and model lock-in — logic baked into weights you can't inspect or change. The way to de-risk a purchase is to insist on transparency, measurement, and portability (see how to evaluate AI coding).
A hybrid third way
The build-vs-buy framing assumes you must choose between fit and speed. You don't have to. The strongest position is a bought system that behaves like a built one:
- Built on your data — adapted to your providers' documentation, payers, and coding patterns, so you get build-grade fit.
- Transparent, inspectable rules your team governs — not a black box, so you keep build-grade control.
- No model lock-in — the logic is explicit and portable, not trapped in weights.
- Vendor-maintained — so you skip the in-house AI team and the maintenance treadmill.
How Capsa fits this decision
Capsa is deliberately designed as that hybrid. It's a system you buy, but it's built on your data, its logic lives in explicit, human-readable rules your CDI team governs, and there's no model lock-in — so you get the fit and control of building without standing up a $0.5–1M/year AI team or owning the maintenance and audit-readiness treadmill. And because a pilot runs on a sample of cases you've already coded, you can prove the use case before committing.
Frequently asked questions
Should we build or buy AI medical coding?+
How much does it cost to build AI coding in-house?+
What's the hidden cost of building?+
Is there a middle option between build and buy?+
Sources
- Build-vs-buy software frameworks in the age of AI (TCO, maintenance, breakeven). hatchworks.com
- Industry analysis of AI medical coding software development and in-house team cost. emorphis.health